A Quarterly Newsletter from GeneInsightIssue 4: November 2014
We are pleased to share the Fall 2014 edition of our newsletter, GeneInsights. In this edition, we feature a Letter to the Editor from Sandy Aronson, Executive Director of IT at Partners Personalized Medicine and a Q and A session with Chris Callahan, Vice President of Diagnostic Solutions, Sunquest Information Systems.
We hope you enjoy the latest issue of GeneInsights. Happy Fall!
Letter to the Editor
Samuel “Sandy” Aronson is the Executive Director of IT at Partners Personalized Medicine
Our partnership with Sunquest is one of the most significant events in the history of GeneInsight. We believe it will benefit our customers, the GeneInsight product itself and the field overall in several important ways.
Customers are currently seeking end-to-end solutions to both strengthen and simplify support for their testing workflows. This broad support requires deep integration between GeneInsight’s reporting and knowledge management functionality and pathology laboratory information systems (LIS). Through this partnership we will develop out of the box integrations between the Sunquest and GeneInsight product lines and offer this support to the 1,700 hospitals running Sunquest solutions. Sunquest will also begin spreading the word about our VariantWire network. We will be working together to make VariantWire available to more institutions thereby continuing to increase the power of the network for all participants.
However, the most exciting aspect of this partnership is the ground work we will be laying to bring genetic, genomic and pathology data together. Fully realizing the value of clinical genetics will require much more holistic and integrated approaches than are currently possible today. GeneInsight and Sunquest will be exploring how to build and distribute infrastructure aimed at enabling laboratories to increase the impact of their clinical genetic and pathology tests. Our goal is to provide laboratories with the support that will make it easier for them to advance the standards of care that underlie personalized medicine.
Q & A Session with Chris Callahan, Vice President of Diagnostic Solutions, Sunquest Information Systems
Can you tell me what motivated Sunquest’s decision to move into the genetics market?
Our goal is to help accelerate the process to establish genetics and personalized medicine as the clinical standard. We believe the market is ready to breakthrough from research to clinical applications and that we can help bring that transformation about. Further, we have spent the last two years looking at all the various efforts out there and have found none to be nearly as complete and as clinically proven as GeneInsight. You add on top of that the opportunity to have a long-term collaboration with Partners HealthCare and the Laboratory for Molecular Medicine, a world-leader in the clinical application of genetics, and it really was a no-brainer for us.
Sunquest has collaborated with Partners HealthCare in the past on anatomical pathology, why do you think this relationship continues to work so well?
We have had a very successful, long-term relationship with Partners HealthCare. They are currently implementing enterprise wide LIS on Sunquest. This new partnership is a natural extension of what we have already done together. At Sunquest, we believe our clients are our greatest assets and only by being close to them can we understand how to best solve the problems they face today, and the challenges they will meet tomorrow. I think the reason we continue to work so well together is that both organizations have a dual focus on the patient and on innovation. Personally, I love working with driven, smart people who realize they are part of something bigger.
Why did Sunquest choose the GeneInsight platform?
As I mentioned earlier, we have looked at all the available offerings in the market and have found that most systems being marketed have very little clinical experience. GeneInsight has been in continuous clinical use since 2005 and has produced almost 40,000 clinical reports. No one else out there even comes close. We are also on board with the vision behind data sharing. While GeneInsight was the most robust solution we found, we see VariantWire, the data-sharing network established by GeneInsight, as being a huge differentiator. In addition to the software and the insightful strategy, we have been extraordinarily impressed with the GeneInsight team. They are dedicated to the idea of bringing precision medicine to the masses and really understand what is needed to accomplish this because of their depth of experience.
Why does Sunquest think data sharing efforts, like VariantWire, are important to the field of genetics?
Sunquest, as a best of breed vendor, is dedicated to open systems and interoperability. We see data sharing efforts like Variant Wire as an extension of that philosophy. There is so much to be learned and so much changing in the field that a closed, proprietary approach to advancing genetic knowledge makes no sense to us. The more systems are open, the more data is ‘free’, the more the health care system benefits and the more value for our customers. This idea is particularly crucial when it comes to genetics. With all the new knowledge being generated every day we see data sharing efforts such as VariantWire as crucial to bringing genetics into the mainstream.
How will the market benefit from these two organizations working together?
Sunquest is the market leader in laboratory IT. We have a significant market presence in both the clinical and the anatomic pathology segment. These fields have been separate in the past but complex testing, genetics and molecular, are forcing them together. Our clients realize that. When you take Sunquest and combine it with the knowledge of the GeneInsight team and what they have built over the past decade, you have the ability to produce a highly differentiated, industrial strength clinical solution. I truly see healthcare advancing as a result of this partnership. I know this is a grandiose thing to say but that is what we aspire to.
What is your long term IT vision in the genetics space? How will this collaboration help you get there?
Our vision here is simple – we want to make genetics and precision medicine a standard of care. Not a rare exception, reserved for the few, but accessible by all, in a proactive form of medicine. We talk about the $1,000 sequence but the $100,000 interpretation. Our goal is to solve the $100,000 interpretation problem. We will reduce the complexity, cost and time of genetic testing so that clinicians will have access to the best information available to truly inform and impact patient care.
Assessments in the News
The articles included in the ‘Assessment in the News’ are offered only for general informational and educational purposes.
GeneInsight in the News
Sunquest and GeneInsight will collaborate on providing seamless genetic testing workflow capabilities to clinical geneticists and pathologists.
Sunquest Information Systems and Partners HealthCare in Boston are expanding their long-running partnership to accelerate genomics-based medicine.
GeneInsight will be exhibiting at the following conferences in 2014. If you are interested in meeting with a team member, please stop by our booth or contact email@example.com to schedule a demo.
November 12-15, 2014, National Harbor, MD